Drug Trial Radar · NCT07911553
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Dec 22, 2026
Primary completion
Sep 2, 2030
Study completion Sep 1, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to \< 80 years of age with previously untreated large B-cell lymphoma (LBCL) with International Prognostic Index (IPI) score 2 to 5.
Conditions
- Large B-cell Lymphoma
Interventions
SurovatamigDrug
Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody
RituximabDrug
Rituximab will be administered to participants as per SoC.
CyclophosphamideDrug
Cyclophosphamide will be administered to participants as per SoC.
DoxorubicinDrug
Doxorubicin will be administered to participants as per SoC.
VincristineDrug
Vincristine will be administered to participants as per SoC.
PrednisoneDrug
Prednisone (or equivalent) will be administered to participants as per SoC.
Polatuzumab vedotinDrug
Polatuzumab vedotin will be administered to participants as per SoC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) as assessed by Blinded Independent Central Review (BICR)Time frame: Up to 10 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.